Pamela Munster, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Pamela Munster, MD

Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Early Phase Clinical Trials Unit and Leader, Developmental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 353-7070 (appts)
Box 1711, UCSF
San Francisco, CA 94143-1711

View on UCSF Profiles

Cancer Center Membership

Program Member » Breast Oncology» Developmental Therapeutics

Research Summary

My clinical research interests are first-in-human early phase clinical trials of novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved in clinical and translational research in early phase clinical trials since 1998. As the program leader for Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies and molecular imaging for patients with advanced stage cancer.

My basic research interest is centered on the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.

Education

Kantonsschule Sargans, Switzerland, Baccalaureate, 1983, Sciences, Liberal Arts
University of Bern Switzerland, Doctorate, 1990, Medicine
University of Bern Switzerland, MD Thesis, 1992, Medicine


Professional Experience

  • 1990-1992
    University of Bern, Department of Physiology, Teaching Assignment in Physiology
  • 1992-1993
    Indiana University at Indianapolis, Krannert Institute of Cardiology
  • 1993-1996
    Residency in Internal Medicine Indiana University Medical Center at Indianapolis
  • 1996-1999
    Hematology-Oncology Fellowship at Memorial Sloan Kettering Cancer Center/The New York Hospital-Cornell Medical Center New York
  • 1999-2000
    Research Associate, Department of Medicine, Breast Program, Memorial Sloan Kettering Cancer Center, New York
  • 2000-2001
    Clinical Assistant Member, Memorial Sloan Kettering Cancer Center, Department of Medicine, Breast Cancer Service
  • 2001-2006
    Assistant Professor: Division of Breast Oncology & Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research Institute; Division of Medical Oncology & Hematology, Dept of Internal Medicine, University of South Florida
  • 2006-2008
    Associate Professor: Division of Breast Oncology & Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research Institute; Division of Medical Oncology & Hematology, Dept of Internal Medicine, University of South Florida
  • 2007-present
    Faculty Affiliate, Colorade State University, Ft. Collins, CO
  • 2008-2010
    Associate Professor in Residence, Department of Medicine, Division of Hematology/Oncology, UCSF
  • 2008-present
    Director, Early Phase Clinical Trials Program and Associate Director, Investigational Therapeutics, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2010-present
    Professor in Residence, Department of Medicine, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 1998
    John Mendelsohn House staff Teaching Award
  • 1999
    AACR-AFLAC Young Investigators Scholar Award 1999
  • 2000, 2001
    Byrne Fund Award
  • 2003-2005
    Don Shula Career Development Award, 2003-2005
  • 2007-2008
    Greatest Number of Investigator-Initiated Trials Written & Implemented, H. Lee Moffitt Cancer Center & Research Institute
  • 2008
    Research Highlights, Department of Defense, Congressionally Directed Medical Research Programs

Selected Publications

  1. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81.
    View on PubMed
  2. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer. 2015 Sep; 51(14):1865-73.
    View on PubMed
  3. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clin Cancer Res. 2015 Dec 1; 21(23):5235-44.
    View on PubMed
  4. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 1; 121(19):3481-90.
    View on PubMed
  5. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8.
    View on PubMed
  6. More Options for Fertility Preservation for Patients With Cancer. J Clin Oncol. 2015 Aug 1; 33(22):2413-5.
    View on PubMed
  7. Ovarian protection during adjuvant chemotherapy. N Engl J Med. 2015 Jun 4; 372(23):2268-9.
    View on PubMed
  8. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics. 2015 Jun; 7(4):641-52.
    View on PubMed
  9. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015; 17(1):26.
    View on PubMed
  10. Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors. J Clin Oncol. 2015 Mar 20; 33(9):1060-6.
    View on PubMed
  11. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014 Aug; 74(2):359-65.
    View on PubMed
  12. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opin Pharmacother. 2014 Jun; 15(9):1277-88.
    View on PubMed
  13. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9.
    View on PubMed
  14. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar; 73(3):467-73.
    View on PubMed
  15. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014 Feb 15; 20(4):1029-41.
    View on PubMed
  16. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Cancer Chemother Pharmacol. 2014 Jan; 73(1):103-11.
    View on PubMed
  17. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med. 2013 Aug 14; 5(198):198ra108.
    View on PubMed
  18. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther. 2013 Oct; 12(10):2078-87.
    View on PubMed
  19. Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One. 2013; 8(7):e68973.
    View on PubMed
  20. Fertility preservation and breast cancer: A complex problem. Oncology (Williston Park). 2013 Jun; 27(6):533-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI